The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
Authors:
- Christian BlankCBChristian Blank
- Simon ChowdhurySCSimon Chowdhury
- Simon HorenblasSHSimon Horenblas
- John PetersJPJohn Peters
- Jonathan ShamashJSJonathan Shamash
- Naveed SarwarNSNaveed Sarwar
- Ekaterini BoletiEBEkaterini Boleti
- Anju SahdevASAnju Sahdev
- Tim O'BRienTOTim O'BRien
- Dan BerneyDBDan Berney
- Luis BeltranLBLuis Beltran
- 1 September 2011
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 60 (3) , 448-454
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancerAnnals of Oncology, 2011
- The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted TherapyJournal of Urology, 2011
- Prospective Clinical Trial of Preoperative Sunitinib in Patients With Renal Cell CarcinomaJournal of Urology, 2010
- Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell CarcinomaJournal of Clinical Oncology, 2010
- Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibBritish Journal of Cancer, 2010
- Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markersBMC Cancer, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989